Karyopharm Therapeutics Crescita futura
Criteri Future verificati 2/6
Si prevede che Karyopharm Therapeutics aumenterà gli utili e i ricavi rispettivamente del 53.9% e 30.5% all'anno, mentre si prevede che l'EPS crescerà del 68.9% all'anno.
Informazioni chiave
53.9%
Tasso di crescita degli utili
68.93%
Tasso di crescita dell'EPS
| Biotechs crescita degli utili | 24.9% |
| Tasso di crescita dei ricavi | 30.5% |
| Rendimento futuro del capitale proprio | n/a |
| Copertura analitica | Good |
| Ultimo aggiornamento | 08 Jun 2026 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Aggiornamento della narrazione • Jun 07
KPTI: Phase 3 Myelofibrosis Data Will Drive 2026 Frontline Opportunity
Analysts have revised their price target on Karyopharm Therapeutics, citing updated views on fair value, growth, and profitability assumptions. The new target is $13.50, compared with the prior $15.33.
Aggiornamento della narrazione • May 03
KPTI: Selinexor Commercialization And Funding Pressures Will Likely Constrain Future Upside
Analyst price targets for Karyopharm Therapeutics have shifted, with recent cuts and a subsequent $8 increase tied to reassessments of revenue potential, profit margins and future P/E assumptions around selinexor and the broader pipeline. Analyst Commentary Recent Street research on Karyopharm Therapeutics shows a mixed picture, with one price target increase following several cuts over a relatively short window.Aggiornamento della narrazione • Apr 19
KPTI: Funding Uncertainty And Execution Risks Will Likely Cap Future Returns
Analysts have trimmed their average price target on Karyopharm Therapeutics by several dollars, citing updated views on discount rates, revenue assumptions and long term profit margins following recent Street research. Analyst Commentary Recent Street research shows several bearish analysts cutting their Karyopharm price targets by mid single digit to high single digit dollar amounts, pointing to revised assumptions on discount rates, revenue potential and long term margins.Aggiornamento della narrazione • Apr 04
KPTI: Funding Strains And Execution Risks Will Likely Restrain Future Upside
The Street’s blended fair value estimate for Karyopharm has been trimmed by $1.00 to $5.00, as analysts fold in lower projected revenue growth, a slightly softer profit margin outlook, a higher discount rate, and updated P/E assumptions following recent target cuts from multiple firms. Analyst Commentary Recent Street research has tilted more cautious on Karyopharm, with multiple bearish analysts cutting price targets and reassessing the risk profile around execution, profitability, and the timing and scale of future revenue contributions.Seeking Alpha • Mar 26
Karyopharm: Putting The Phase 3 Trial In Context
Summary Karyopharm Therapeutics faces heightened uncertainty after mixed phase 3 SENTRY results for selinexor in myelofibrosis. KPTI met the spleen volume reduction endpoint but missed symptom improvement while showing a promising, though immature, overall survival signal. A dire cash position persists despite a $30 million private placement; the runway extends only into Q2 2026, with existential funding risks looming. I maintain a tentative 'Buy' rating, citing deep pessimism and multiple 2026 catalysts, but caution against aggressive position sizing due to liquidity and funding risks. Read the full article on Seeking AlphaAggiornamento della narrazione • Mar 21
KPTI: Phase 1 Myelofibrosis Data Will Support 2026 Frontline Opportunity
Analysts have adjusted their price target for Karyopharm Therapeutics to $28, citing confidence in selinexor's differentiated mechanism of action, compelling Phase 1 data in myelofibrosis, and a projected peak revenue opportunity of $800m to $850m in frontline myelofibrosis, with further potential from multiple myeloma programs. Analyst Commentary Bullish Takeaways Bullish analysts see selinexor's differentiated mechanism of action as a key driver for long term value, supporting the $28 price target as they factor in a distinct clinical profile within myelofibrosis.
Aggiornamento della narrazione • Mar 07
KPTI: Refreshed Revenue And Margin Outlook Will Support Bullish Repricing
Analysts have updated their price target on Karyopharm Therapeutics from $66.25 to $23.00, citing refreshed assumptions around revenue growth, profit margins, discount rate, and future P/E following recent bullish Street research. Analyst Commentary Bullish analysts are framing the reset in price target to $23.00 as part of a broader constructive view on Karyopharm Therapeutics, where refreshed modeling assumptions are more closely aligned with recent positive Street research.Aggiornamento della narrazione • Feb 20
KPTI: Execution And Funding Risks Will Likely Cap Bullish Repricing
Analysts have raised their $6.00 price target for Karyopharm Therapeutics, citing slightly lower perceived risk, a modestly stronger revenue outlook, and a small increase in the expected future P/E as the key factors behind the update. Analyst Commentary Recent research commentary around Karyopharm Therapeutics has centered on how much risk investors should assign to the story, how sustainable the current revenue trajectory may be, and what a reasonable P/E might look like given execution needs ahead.Aggiornamento della narrazione • Feb 06
KPTI: Lower Risk View Will Support 2026 Myelofibrosis Phase III Milestone
Analysts have modestly raised their price target on Karyopharm Therapeutics to US$15.33, citing a slightly lower required return and similar long term growth and margin assumptions that keep the fair value estimate steady. Analyst Commentary Recent Street research has focused on how the updated price target for Karyopharm Therapeutics lines up with its risk profile and execution needs, rather than materially changing long term growth or margin assumptions.Aggiornamento della narrazione • Jan 23
KPTI: Extended Cash Runway Will Support 2026 Myelofibrosis Phase III Milestone
Narrative update on Karyopharm Therapeutics Analysts have nudged their fair value estimate for Karyopharm Therapeutics higher from US$14.67 to US$15.33, citing recent Street research that points to steady Xpovio sales, reduced financing overhangs, maintained MF timelines into March 2026, and updated price targets that reflect the latest financing transactions. Analyst Commentary Recent Street research highlights a mix of optimism around execution and caution around financing and valuation as analysts update their views on Karyopharm Therapeutics.Articolo di analisi • Jan 11
Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Prospects Need A Boost To Lift Shares
You may think that with a price-to-sales (or "P/S") ratio of 1.1x Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) is...Aggiornamento della narrazione • Jan 09
KPTI: Financing Overhangs Will Likely Outweigh MF Timeline Support
Analysts have trimmed their 12 month price target on Karyopharm Therapeutics to US$19 from US$30, citing recent financing transactions. They also point to solid Xpovio sales and maintained MF timelines into March 2026 as support for the stock’s overall risk and reward profile.Aggiornamento della narrazione • Dec 25
KPTI Extended Cash Runway Will Likely Be Outweighed By Dilution Risk
Analysts have cut their price target on Karyopharm Therapeutics to about $6 from roughly $8 per share, citing the impact of recent financing transactions on valuation. At the same time, extended cash runway, solid Xpovio sales and visibility into key 2026 myelofibrosis data support a still constructive risk and reward profile.Aggiornamento della narrazione • Dec 11
KPTI: Extended Cash Runway Will Support Pivotal 2026 Myelofibrosis Phase III Readout
Analysts have modestly reduced their price targets on Karyopharm Therapeutics, trimming expectations from a prior average in the low $20s to the high teens. Recent financing transactions extend the cash runway into 2026 and also dilute near term upside, despite a solid outlook for Xpovio sales and key myelofibrosis data in 2026.Aggiornamento della narrazione • Nov 27
KPTI: Extended Cash Runway Will Support Key Myelofibrosis Phase III Data
Analysts have lowered their price targets on Karyopharm Therapeutics, with reductions such as $19 from $30 and $6 from $8. They cite the impact of recent financing transactions while maintaining positive views on the company's risk profile and its cash runway extension, which is expected to support upcoming trial milestones.Aggiornamento della narrazione • Nov 11
KPTI: Upcoming Myelofibrosis Phase III Readout Will Drive Future Opportunity
Karyopharm Therapeutics’ analyst fair value price target has decreased by $1.00 to $14.67. Analysts cite recent financing transactions and updated growth forecasts as key factors behind the revision.Aggiornamento della narrazione • Oct 28
Extended Cash Runway Will Support Pivotal Phase III Clinical Milestones
Karyopharm Therapeutics' analyst price target has been reduced sharply from approximately $23.07 to $15.67 per share. Analysts cite the company’s recent strategic financing measures and updated projections following extended cash runway and upcoming clinical milestones.Aggiornamento della narrazione • Oct 13
Phase III Trials And Global Partnerships Will Advance Personalized Medicine
Karyopharm Therapeutics' analyst price target has been reduced from $8 to $6. This reflects analysts' views that, while strategic financing has extended the company's cash runway into Q2 2026, financial constraints and the timeline to key clinical trial readouts warrant a tempered outlook.Articolo di analisi • Sep 11
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Held Back By Insufficient Growth Even After Shares Climb 65%
Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) shares have had a really impressive month, gaining 65% after a shaky...Aggiornamento della narrazione • Aug 15
Phase III Trials And Global Partnerships Will Advance Personalized Medicine
Karyopharm Therapeutics’ net profit margin has improved and its future P/E has declined—indicating stronger profitability and a more attractive valuation—while the consensus analyst price target remains unchanged at $25.92. What's in the News Provided 2025 earnings guidance, expecting total revenue between $140 million and $155 million, including U.S. XPOVIO net product and partner-derived revenue.Articolo di analisi • Aug 14
US$25.92: That's What Analysts Think Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Is Worth After Its Latest Results
NasdaqGS:KPTI 1 Year Share Price vs Fair Value Explore Karyopharm Therapeutics's Fair Values from the Community and...Articolo di analisi • May 24
Investors Don't See Light At End Of Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Tunnel And Push Stock Down 27%
Unfortunately for some shareholders, the Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) share price has dived 27% in the...Articolo di analisi • May 22
Here's Why Shareholders May Want To Be Cautious With Increasing Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) CEO Pay Packet
Key Insights Karyopharm Therapeutics' Annual General Meeting to take place on 28th of May CEO Richard Paulson's total...
Nuova narrazione • Apr 08
Phase III SENTRY And XPOVIO Approvals Will Secure Future Success
Positive trial outcomes in myelofibrosis and endometrial cancer could significantly boost revenue and redefine care standards.Articolo di analisi • Dec 24
Lacklustre Performance Is Driving Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) 27% Price Drop
Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) shareholders won't be pleased to see that the share price has had a very...Articolo di analisi • Oct 01
Why Investors Shouldn't Be Surprised By Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Low P/S
You may think that with a price-to-sales (or "P/S") ratio of 0.7x Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) is...Articolo di analisi • Aug 09
Karyopharm Therapeutics Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Shareholders might have noticed that Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) filed its second-quarter result this...Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Utili | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2028 | 230 | -117 | N/A | N/A | 4 |
| 12/31/2027 | 155 | -135 | N/A | N/A | 6 |
| 12/31/2026 | 137 | -128 | N/A | N/A | 7 |
| 3/31/2026 | 151 | -195 | N/A | N/A | N/A |
| 12/31/2025 | 146 | -196 | -75 | -75 | N/A |
| 9/30/2025 | 143 | -125 | -89 | -89 | N/A |
| 6/30/2025 | 137 | -124 | -103 | -103 | N/A |
| 3/31/2025 | 142 | -63 | -123 | -123 | N/A |
| 12/31/2024 | 145 | -76 | -128 | -127 | N/A |
| 9/30/2024 | 148 | -87 | -120 | -120 | N/A |
| 6/30/2024 | 146 | -90 | -131 | -130 | N/A |
| 3/31/2024 | 140 | -141 | -118 | -118 | N/A |
| 12/31/2023 | 146 | -143 | -93 | -93 | N/A |
| 9/30/2023 | 146 | -140 | -101 | -101 | N/A |
| 6/30/2023 | 146 | -142 | -100 | -100 | N/A |
| 3/31/2023 | 148 | -158 | -109 | -109 | N/A |
| 12/31/2022 | 157 | -165 | -150 | -150 | N/A |
| 9/30/2022 | 250 | -88 | -97 | -97 | N/A |
| 6/30/2022 | 251 | -104 | -99 | -93 | N/A |
| 3/31/2022 | 234 | -108 | -119 | -113 | N/A |
| 12/31/2021 | 210 | -124 | -113 | -107 | N/A |
| 9/30/2021 | 119 | -206 | -169 | -163 | N/A |
| 6/30/2021 | 102 | -208 | -184 | -184 | N/A |
| 3/31/2021 | 113 | -201 | -168 | -168 | N/A |
| 12/31/2020 | 108 | -196 | -160 | -160 | N/A |
| 9/30/2020 | 91 | -201 | -169 | -169 | N/A |
| 6/30/2020 | 83 | -189 | -161 | -161 | N/A |
| 3/31/2020 | 59 | -186 | -169 | -169 | N/A |
| 12/31/2019 | 41 | -200 | N/A | -191 | N/A |
| 9/30/2019 | 23 | -209 | N/A | -200 | N/A |
| 6/30/2019 | 10 | -216 | N/A | -202 | N/A |
| 3/31/2019 | 20 | -206 | N/A | -191 | N/A |
| 12/31/2018 | 30 | -178 | N/A | -159 | N/A |
| 9/30/2018 | 32 | -159 | N/A | -116 | N/A |
| 6/30/2018 | 31 | -142 | N/A | -100 | N/A |
| 3/31/2018 | 12 | -138 | N/A | -84 | N/A |
| 12/31/2017 | 2 | -129 | N/A | -74 | N/A |
| 9/30/2017 | 0 | -117 | N/A | -88 | N/A |
| 6/30/2017 | 0 | -112 | N/A | -87 | N/A |
| 3/31/2017 | 0 | -112 | N/A | -86 | N/A |
| 12/31/2016 | 0 | -110 | N/A | -84 | N/A |
| 9/30/2016 | 0 | -112 | N/A | -85 | N/A |
| 6/30/2016 | 0 | -117 | N/A | -90 | N/A |
| 3/31/2016 | 0 | -119 | N/A | -97 | N/A |
| 12/31/2015 | 0 | -118 | N/A | -94 | N/A |
| 9/30/2015 | 0 | -115 | N/A | -86 | N/A |
| 6/30/2015 | 0 | -104 | N/A | -77 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Si prevede che KPTI rimarrà non redditizia nei prossimi 3 anni.
Guadagni vs Mercato: Si prevede che KPTI rimarrà non redditizia nei prossimi 3 anni.
Guadagni ad alta crescita: Si prevede che KPTI rimarrà non redditizia nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che il fatturato di KPTI ( 30.5% all'anno) crescerà più rapidamente del mercato US ( 12.5% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di KPTI ( 30.5% all'anno) crescerà più rapidamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Dati insufficienti per determinare se il Return on Equity di KPTI è previsto essere elevato tra 3 anni
Scoprire le aziende in crescita
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/06/10 15:43 |
| Prezzo dell'azione a fine giornata | 2026/06/10 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Karyopharm Therapeutics Inc. è coperta da 20 analisti. 7 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Colleen Kusy | Baird |
| Ying Huang | BofA Global Research |
| Harshita Polishetty | B. Riley Securities, Inc. |